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BACKGROUND 
Infections and liver disease are still major problems in renal transplant 
recipients. Bacterial, fungal, and viral infections are presumably related to 
impaired host resistance from immunosuppressive therapy. Liver disease is 
reported in up to 60% of transplant recipients and carries a high mortality. Several 
types of liver disease can occur. The most common are acute and chronic hepatitis.  
The variety of acute hepatitis includes hepatitis A, hepatitis B, hepatitis C, 
cytomegalovirus hepatitis, herpes simplex hepatitis and drug induced hepatitis. 
Chronic hepatitis is a serious problem because the disease seems to be progressive 
despite prednisone therapy.  
Chronic liver disease (CLD) is a frequent complication after renal transplantation, 
representing the fourth cause of death in most series. Hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infection are the most important causes of CLD in renal 
transplant patients. Both HBV and HCV infections have a deleterious effect on 
long-term graft and patient survival in the long run. Also, liver disease is the 
leading cause of death in these infected patients. 
 
 
 
 
 
AIMS  
 
         1. To analyze the clinical profile, etiology and outcome of renal transplant 
recipients presenting with clinical and/or biochemical evidence of hepatic 
dysfunction. 
   2. To assess the impact of HBV and HCV infection on patient and graft survival 
in a group of kidney transplanted patients.  
   3. To compare the survival rate of infected patients with noninfected patients.  
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
INCIDENCE 
Liver disease in the post transplantation period is an important complication that 
could adversely affect the clinical outcomes of renal transplantation. The reported 
incidence of post transplantation liver disease among renal transplant recipients 
varies widely between 1% and 67% (1-4). 
This wide variation reflects differences in the diagnostic criteria, accuracy in 
establishing the diagnosis and the length of the follow-up in establishing the 
diagnosis and the length of the follow -up period (liver disease is more likely to 
manifest itself with increasing number of years post transplantation). However, the 
real incidence of post transplantation liver disease seems to be unknown. 
The reported data do not reflect the true incidence and prevalence of ALD and 
CLD because cases of ALD with relatively mild presentation and recovery without 
any sequelae as well as cases of CLD with a silent clinical and no tendency to 
progression are less likely to be recognized than cases presenting with more severe 
acute liver injury or rapid progression to clinically overt CLD (6, 10). 
CLINICAL PRESENTATION AND BIOCHEMICAL SPECTRUM 
In about 80% of the patients with liver disease the clinical symptoms and / or 
laboratory abnormalities occur within 6 months (peak between 8 and 12 weeks) 
from the date of transplantation (2, 13). 
Complaints are mainly constitutional, vague or mild and not infrequently, the 
patient can be asymptomatic. Physical findings characteristic of liver disease, such 
as jaundice, hepatosplenomegaly, spiders or any other symptoms of portal 
hypertension are usually absent unless the liver disease progresses to very 
advanced stages (4, 6, 8). Fulminant hepatitis presenting with rapid deterioration, 
jaundice, encephalopathy and fatal outcome due to severe hepatocellular failure is 
extremely rare and has been reported only in recipients with hepatitis B 
antigenemia co-infected with delta agent, or in association with hepatotoxic drugs, 
other forms of viral hepatitis, or multiorgan failure (16).Consequently the clinical 
presentation alone does not provide enough evidence for the timely diagnosis of 
post transplantation liver disease. 
The incidence of liver function test (LFT) abnormalities among kidney transplant 
recipients varies widely from 3% to 60 %( 8, 9, 11, and 13). 
Mild and transient LFT abnormalities are most common in the first 6 months post 
transplantation, while others have noted that the prevalence of LFT abnormalities 
increases with the time after transplantation. This discrepancy possibly reflects, on 
one hand, the more comprehensive evaluation of transplant recipients commonly 
performed early post transplantation that may lead to more frequent detection of 
acute liver disease early rather than later in the post transplantation period or on 
the other hand, a true increase in the incidence of clinically overt liver disease in 
the late post transplantation period as a result of the relentless progression of some 
forms of CLD to more advanced stages. 
LFTs are an imperfect tool for the diagnosis of post transplantation liver disease 
because first, LFT abnormalities are generally not associated with clinical 
symptoms (except in the case of advanced liver disease and liver failure) and 
secondly, histological evidence of advanced liver disease can be present in the 
absence of abnormal LFT(9). 
 
LIVER HISTOLOGY 
Liver biopsy is recommended in all kidney transplant recipients with documented 
abnormal LFT with duration of 6 or more months, irrespective of possible 
etiology, unless there are factors that could increase the risk from the procedure 
(i.e., prothrombin time >15 sec, bilirubin higher than 10 mg/dL, clinically unstable 
condition or a systemic infection). Liver histology is essential for the precise 
diagnosis of post transplantation liver disease and provides more useful prognostic 
information than any biochemical test. 
The most common histological patterns of liver disease in kidney transplant 
recipients are 
Fat Metamorphosis: 
 Lipid droplets within the hepatocytes characterize this lesion. 
Hepatitis: 
 Hepatitis of varying degrees and severity is the most common histological 
findings on liver biopsy. 
(a) Chronic persistent hepatitis (CPH) presents with inflammatory cell infiltration 
limited to the portal triad with no disruption of the limiting plate. 
(b) Early chronic active hepatitis (CAH) is notable for the extension of the 
inflammatory cell infiltration beyond the portal triad into the hepatic lobule and 
the absence of piecemeal necrosis, bridging hepatic necrosis or fibrosis. In some 
series, CAH has been reported as the most common from of post transplantation 
liver disease. 
(c) Advanced chronic active hepatitis presents with extensive cellular infiltration 
(Lymphocytes, plasma cells, and neutrophils) with disruption of the limiting plate 
and bridging hepatic necrosis involving multiple lobules. 
Micro nodular cirrhosis: 
 The liver parenchyma is distorted by abundant scar tissue and formation of 
pseudonodules 
Intra hepatic cholestasis: 
The histology is dominated by severe pericentral cholestasis, without parenchymal 
necrosis or involvement of the portal triad. In kidney transplant recipients, this 
lesion has been associated with nonspecific reactive hepatitis secondary to sepsis, 
azathioprine therapy or viral hepatitis. Intrahepatic cholestasis is a completely 
reversible condition although it may continue for a prolonged period of time. 
Fibrosing cholestatic hepatitis: 
 This is a rare and extremely severe form of hepatitis B initially reported in liver 
transplant recipients, but recently also observed in kidney transplant recipients. 
The histology is notable for severe periportal fibrosis, cholestasis, widespread 
balloon degeneration of hepatocytes, and only a mild infiltration of inflammatory 
cells. Progression is relentless and fatal, commonly within a few months of 
diagnosis. 
Vanishing bile duct syndrome: 
 The lesions associated with this syndrome affect the small-sized interlobular bile 
ducts. Early histology reveals degenerative changes of the epithelium of the bile 
ducts. Later on, histological findings are consistent with more severe damage and 
ultimately with progression to bile duct loss. In kidney transplant recipients, this 
syndrome has been specifically associated with hepatitis B and C virus. 
Hemosiderosis: 
 This lesion is characterized by accumulation of excessive iron within the 
hepatocytes. 
Peliosis hepatis: 
 The histological picture is notable for irregularly dilated sinusoids, which contain 
erythrocytes and form cavities with irregular size, shape and distribution in the 
liver parenchyma. These sinusoids are filled with blood and are often surrounded 
by atrophic liver cell cords that lack an endothelial lining. Bile stasis and 
inflammatory changes are absent.The etiology and pathogenesis of this disorder 
are unknown. A strong association with azathioprine therapy has been considered 
as all cases of peliosis hepatis in kidney transplant recipients have occurred among 
those treated with azathioprine. Other possible causes included infections with 
hepatitis A virus (HAV); hepatitis B virus (HBV); hepatitis C virus (HCV); 
cytomegalovirus (CMV); herpes simplex virus (HSV); malignancy; tuberculosis; 
diabetes; use of anabolic, androgenic and estrogenic corticosteroid agents; and 
therapy with alpha-methyldopa or tamoxifen. 
Nodular regenerative hyperplasia (NRH):  
This condition is characterized by diffuse micronodular transformation of the 
hepatic parenchyma without fibrous septa between the nodules. The exact 
pathogenesis of this disorder has not been established. However, the nodular 
transformation is suspected to originate from obliteration of the portal veins. 
Different etiologies have been suggested and among these, azathioprine therapy 
seems to be the most favored. NRH may present with clinical features of portal 
hypertension and mild cholestasis. 
Venoocclusive disease (VOD):  
The hallmark of this lesion is nonthrombotic obliterative occlusion of the terminal 
hepatic venules and sublobular veins by loose connective tissue, with adjacent 
sinusoidal congestion and dilatation and hepatocellular degeneration or 
necrosis.The etiology and pathogenesis of VOD are unclear. It is speculated that 
immunosuppression induced by azathioprine together with hepatic viral insult 
could cause endothelial cell damage, which will ultimately progress to the 
development of this disorder. The prognosis is very grim, usually with fatal 
outcome. 
Etiology of liver disease in kidney transplant recipients 
The etiology of liver disease in kidney transplant recipients is complex. Numerous 
drugs, systemic viral infections with herpes viruses, infections with hepatitis virus 
as well as different co morbid conditions, such as bacterial infections, sepsis, 
hemolysis, graft versus host disease, congestive heart failure, intrinsic liver disease 
and many others can cause liver injury, which may lead to the development of 
chronic liver disease. However, the most important causes of post transplantation 
liver diseases directly associated with the transplantation itself are drug induced 
hepatotoxicity and chronic infections with hepatitis viruses. 
Drug induced hepatotoxicity 
Azathioprine 
Azathioprine is a purine antimetabolite, introduced as an immunosuppressive 
agent in solid organ transplantation in 1961. In kidney transplant recipients; this 
drug can induce dose - dependent liver injury (6). The pathogenesis of 
azathioprine hepatotoxicity, although incompletely understood, seems to involve 
direct injury to hepatic endothelial cells, hepatocytes and intralobular ducts (17). 
The clinical presentation of azathioprine hepatotoxicity varies widely from 
isolated moderate to severe jaundice, sometimes with marked pruritus to fully 
manifested portal hypertension with ascites, variceal hemorrhage, and severe 
edema. Biochemical abnormalities are consistent with cholestatic pattern of liver 
injury bilirubinemia with increased serum levels of alkaline phosphate and gamma 
- glutamyltranspeptidase). These abnormalities, commonly improve or resolve 
with a decrease in azathioprine dose or with its discontinuation, but recur in about 
50% of the patients if the drug is reinstituted. 
The spectrum of azathioprine - related histological lesions on liver biopsy includes 
peliosis hepatis, perisinusoidal fibrosis, venoocclusive disease, nodular 
regenerative hyperplasia, hepatic sinusoidal dilatation and intrahepatic cholestasis. 
Azathioprine induced direct injury to the endothelial cells has been implicated in 
the pathogenesis of the characteristic vascular lesions observed in peliosis hepatis, 
nodular regenerative hyperplasia, and veno-occlusive disease. 
Evidence in support of the role of azathioprine in the etiology of post 
transplantation liver disease was provided recently by a group of French 
investigators. In their report, 21 out of 1,035 patients, who received a kidney 
transplant between 1969 and 1992, were diagnosed with azathioprine-induced 
hepatitis based on the following criteria. (a) Presence of jaundice, which 
disappeared after azathioprine dose reduction or withdrawal (b) absence of any 
other overt explanation of the liver disease (mainly severe cirrhosis, chronic 
alcoholism, other hepatotoxic drugs or biliovesicular disease). (c) Histopathologic 
findings consistent with intrahepatic cholestasis sometimes associated with 
centrilobular hepatocellular necrosis and vascular lesions, which were reversible 
on repeat liver biopsies performed in two patients, 2 and 4 months after 
withdrawal of azathioprine. All patients with azathioprine - induced hepatitis were 
also positive for viral markers of hepatotropic viral infection (HBV RNA, HBsAg 
or anti- HCV).Consequently, the authors speculated that active hepatotropic viral 
infection could predispose to or even induce azathioprine toxicity by causing liver 
disease, which in turn could slow down the catabolism of azathioprine toxic 
metabolites. Therefore, dose reduction or withdrawal of azathioprine during 
diagnostic evaluation and treatment of viral liver disease in patients whose 
immunosuppressive regimens included this medication should be considered. Vice 
versa, it has been speculated that azathioprine itself may play a role in the en-
hancement of HBV replication post transplantation as some authors have observed 
higher HBV DNA levels in kidney transplant recipients whose  
immuno-suppressive regimen included azathioprine as compared to those who 
were treated only with cyclosporine A and low dose steroids. 
The importance of azathioprine hepatotoxicity in the etiology of post 
transplantation liver disease in kidney transplant recipients will most likely 
diminish in the future due to the rarity of this condition, the fall in the prevalence 
of HBV and HCV infection among patients receiving kidney replacement therapy, 
and the replacement of azathioprine by the newer immunosuppressive agent 
Mycophenolate mofetil. 
Cyclosporine - induced Hepatotoxicity 
The pathogenesis of CsA hepatotoxicity has not been completely unveiled. Some 
investigators suspect that the increase in total intracellular calcium concentration 
resulting from hepatocyte exposure to CsA is highly toxic to the hepatocyte 
function and could be responsible for the liver injury. 
The incidence of CsA hepatotoxicity among kidney transplant recipient ranges 
from 4% to 63% (18). 
This wide variation among studies is mainly due to differences in the definition of 
liver disease, the degree of severity of liver injury, CsA dose, follow-up period, 
selection of study population and the presence of confounding factors, such as in-
fection, hemolysis, graft versus host disease, congestive heart failure, drug 
interactions, etc., which could potentially cause liver injury on their own thus 
making it difficult to recognize the real contribution of CsA in the liver damage. 
The incidence of CsA-related hepatotoxic events seems to have decreased over the 
last few years presumably due to the use of a lower dose of CsA as a part of the 
newer immunosuppressive regimen. 
CsA-induced liver disease commonly presents clinically as acute hepatic injury, 
mainly of cholestatic type and occurs early in the post transplantation period, 
usually within the first 3 months (19). 
There is a possible association of CsA with biliary tract disease. (Gall stone 
disease). 
The most common biochemical abnormality is conjugated hyperbilirubinemia 
alone, or in association with minimal elevation in liver enzymes. The increase in 
serum bilirubin appears to be dose-dependent and reversible after dose reduction 
or discontinuation of the drug. 
Other investigators have failed to associate CsA therapy in kidney transplant 
recipients with elevations in serum bilirubin and AST levels. In another study, 
among kidney transplant recipients without preexisting liver disease, CsA-treated 
patients had a lower incidence of post transplantation chronic liver disease than 
azathioprine-treated patients. Further more, it has been reported that kidney 
transplant recipients with preexisting chronic liver disease who were treated with 
CsA did not present any clinical evidence of progression to severe chronic liver 
disease, demonstrated complete normalization of the biochemical abnormalities 
with persistent clinical remission, showed a slightly higher probability of 
remaining stable as compared to azathioprine-treated patients (19), and had liver 
morphology which remained un-changed over follow-up period of 1 year. 
Long term CsA therapy seems un- likely to produce chronic hepatotoxicity. 
Furthermore, CsA might be considered the drug of choice in patients with chronic 
liver disease undergoing kidney transplantation. 
Hepatitis B virus 
Structure of HBV Genome 
Hepatitis B virus is a small, enveloped DNA virus, which is a member of the 
hepadnavirus family (hepatotropic DNA viruses). The viron consists of a surface 
that incorporates the envelope protein, referred to as hepatitis B surface antigen 
(HBsAg) and core, which contains a DNA polymerase, double-stranded DNA, 
core antigen (HBcAg) and a protein subunit of the core, known as "e" antigen 
(HBeAg). 
Serologic Markers of HBV Infections 
The serologic markers used to detect infections with HBV include HBsAg, anti-
hepatitis B surface antigen antibody (HBsAb), antibody to HBcAg (anti-HBc). 
HBcAg and antibody to HBeAg (anti-HBe). Assays for HBV serologic testing are 
commercially available and largely used in practice. The presence of HBsAg 
indicates current HBV infection and implies potential infectivity. The production 
of HBsAb is a manifestation of immunologic response to HBsAg and therefore is 
a marker of prior infection with HBV or immune response to hepatitis B vaccine. 
Anti-HBc of IgM class discloses current or recent infection with HBV, while anti-
HBc of IgG class is a marker of past infection with HBV at undetermined 
time.HBeAg unveils HBV replication, and therefore, a high degree of infectivity. 
In contrast, anti-HBe in the serum of HBsAg carrier coupled with the absence of 
HBeAg and HBV DNA implies lower titer of HBV and lower degree of 
infectivity. 
Epidemiology of HBV infection 
Hepatitis B is a ubiquitous blood borne infection that has worldwide distribution. 
The virus is mainly transmitted by parenteral exposure or sexual contact. Vertical 
transmission, i.e., transmission from chronically infected mothers to their infants 
occur and usually playas a major role in geographic areas where HBV infection in 
endemic. Horizontal transmission among household contacts of HBV carries is 
possible, but rare. Several studies have demonstrated that HBV can be transmitted 
by organ transplantation. 
The incidence and prevalence of HBV infection (HBs - antigenemia) among 
dialysis patients in the United States in the year 2000 were 0.05% and 0.9% 
respectively (29).The prevalence of HBs antigenemia among kidney transplant 
recipients reported in different studies varies widely from 1.8% to 21.3%.The over 
whelming majority of the these infections are acquired prior to transplantation; 
only a very small portion develops due to HBV transmission by an infected graft 
or de novo infection in the post transplantation period.The prevalence of HBsAg 
among kidney transplant recipients decreased significantly from 24.2% before 
1982 to 9.1% after 1982, when routine HBV vaccination of dialysis patients was 
implemented. 
Clinical Course of Hepatitis B Among Kidney Transplant Recipients 
The clinical course of hepatitis B in kidney transplant recipients is usually 
insidious or even asymptomatic due to the state of iatrogenic immunosuppression. 
If present, clinical symptoms most commonly consist of vague complaints of 
general fatigue, malaise or anorexia. Jaundice is rarely present, recognizable, acute 
hepatitis is almost never observed and the disease tends to be discovered in its 
chronic phase. 
Laboratory tests are usually consistent with only mild elevations in the serum 
aminotransferase levels, sometimes in association with jaundice. While liver 
laboratory test abnormalities usually present within the first 12 months of 
transplantation, clinically overt liver disease is not manifested until advance stages 
are established, late in the post transplantation period. 
Serologic testing of HBV infected kidney transplant recipients commonly reveals 
persistent HBs - antigenemia indicating continuous viral replication, likely 
secondary to iatrogenic immunosuppression. Enhanced HBV replication has been 
associated both with increased prevalence and accelerated progression of liver 
disease. Consequently, persistent HBs - antigenemia seems to carry poor 
prognosis. HBV DNA levels might be useful as a non-invasive means of 
monitoring liver disease activity. Peaks in HBV –DNA concentrations may 
correctly identify transition from a relatively quiescent liver disease to an active 
course and alert the clinician to the need of liver biopsy or adjustment of the 
immunosuppressive regimen.A marked decline in the serum HBV DNA 
concentration in those with previously diagnosed CAH may signify progression to 
cirrhosis probably reflecting loss of hepatic mass that harbors the virus. 
Kidney transplant recipients who become HBsAg - positive in the post 
transplantation period when large doses of immunosuppressive drugs are 
commonly used have a higher mortality rate than those who acquire HBs - 
antigenemia prior to transplantation. 
The clinical presentation and the biochemical data among HBsAg - positive 
kidney transplant recipients have shown correlation with liver morphology. Liver 
biopsy can demonstrate histology consistent with advanced disease in the absence 
of any LFT abnormalities and vise versa, it may lack any pathologic changes in 
patients with biochemical evidence of liver dysfunction. Consequently, LFTs 
appear to be a poor predictor of liver disease activity, and liver biopsy remains the 
only means for precise diagnosis and monitoring the degree of liver injury among 
HBsAg - positive kidney transplant recipients. 
Hepatitis B may take a fulminant course with massive hepatic necrosis on liver 
histology and fatal outcome. The pathogenesis of the fulminant liver failure in 
HBs Ag - positive kidney transplant recipient although not completely clarified, 
has been related to co infection or super infection with hepatitis D virus (HDV) or 
rapid cessation of immunosuppressive therapy with subsequent restoration of 
HBV- infected hepatocytes. 
HBsAg - positive kidney transplant recipients also have an increased incidence of 
hepatocellular carcinoma.Furthermore, transplantation itself carries an increased 
risk of malignancy.Hepatocellular carcinoma in HBsAg- positive kidney 
transplant recipient has been reported with variable, but mostly, relatively high 
frequency with mean time period between transplantation and manifestation of the 
tumor ranging from 1 to 320 months. 
It has been estimated that a patient who is HBsAg - positive on the day of kidney 
transplantation has a 30 fold higher relative risk of developing post transplantation 
chronic hepatitis than a HBs Ag negative patient. However, because liver disease 
in HBsAg- positive kidney transplant recipients progresses slowly and becomes 
clinically overt late in the post transplantation period, sufficiently long follow up 
period is needed to allow for disease manifestation. Indeed, only studies with 
follow up extending beyond 3 years have been able to demonstrate an increased 
incidence of liver disease, in general, and of more severe forms of liver disease, in 
particular. 
The type of the immunosuppressive regimen and the type of HBV infection 
reactivation or de novo infection can affect the course of the liver disease in HBs 
Ag - positive kidney transplant recipients.The combination of azathioprine and 
prednisone has been associated with a high incidence of chronic liver disease 
among HBsAg- positive patients. This is due, at least in part, to the hepatotoxic 
effect of azathioprine and the enhanced viral replication induced by high dose 
prednisone. 
CsA - based triple therapy regimen (CsA, azathioprine and prednisone) has been 
associated with a lower incidence of posttransplatnation liver disease among 
HBsAg - positive kidney transplant recipients. This regimen appears to be less 
hepatotoxic and to have less enhancing effect on viral replication because the use 
of CsA allows the employment of lower doses of both azathioprine and 
prednisone. 
A regimen that includes only CsA and prednisone has been associated with the 
lowest incidence of chronic liver dysfunction among HBs Ag - positive kidney 
transplantation recipients and might be the optimal immunosuppressive regimen 
for HBsAg- positive patients undergoing kidney transplantation. Likewise, 
Mycophenolate mofetil might be another safe choice for immunosuppression in 
this population. 
In contrast, other investigators have failed to detect any correlation between the 
type of the immunosuppressive regimen and the occurrence of hepatitis among 
HBsAg- positive kidney transplant recipients. In these studies, there was no 
statistically significant difference in the risk of developing chronic hepatitis and 
cirrhosis among patient treated with azathioprine as compared to those who 
receive CsA therapy. 
Reactivation of HBV (manifested serologically with reappearance of HBeAg and / 
or HBV DNA in the serum) occurs frequently in chronic HBsAg carriers in the 
post transplantation period. Among kidney transplant recipients, the overwhelming 
majority of cases of chronic hepatitis B results from persistence and/ or 
reactivation of viral replication in the post transplantation period. 
De novo HBV infection is relatively rare. However, de novo HBV infection in the 
post transplantation period has a more aggressive clinical course and a worse 
prognosis. 
Liver Histology 
A number of studies have associated HBs - Antigenemia in kidney transplant 
recipients with more advanced histological forms of liver disease on initial liver 
biopsy, marked tendency to morphologic progression and increased risk of 
developing advanced stages of liver disease, in particular liver cirrhosis. 
HBsAg - negative patients have predominantly benign histological lesions (fat 
metamorphosis and chronic portal triaditis), while HBsAg- positive patients 
commonly present with more severe histological forms of liver disease (CPH, 
CAH and cirrhosis). Furthermore, it has been reported that the incidence of liver 
cirrhosis on initial liver biopsy was 42% in HBsAg - positive recipients versus 
19% in HBsAg- negative recipients. 
Another severe form of liver damage, vanishing bile duct syndrome, has been 
reported in kidney transplant recipients co infected with HBV and HCV. This 
syndrome results from severe injury, and ultimately complete loss, of the small 
size interlobular bile ducts. Its clinical course is notable for rapidly worsening 
cholestasis and fatal outcome. 
The relentless progression of the post transplantation liver disease in HBV 
infected kidney transplantation recipients has not been unanimously supported by 
currently published data indeed, some investigators have failed to detect any 
significant tendency to histolopathological deterioration on serial liver biopsies of 
HBsAg - positive kidney transplant recipients. 
Transmission of HBV Infection by Kidney Transplantation 
Role of donor/ recipient serologic status. The risk of HBV transmission by organ 
transplantation can be predicted from the serologic status of both donor and 
recipient. Kidneys from HBsAg- positive donors are at a high risk of transmitting 
HBV infection to their recipients if these recipients are susceptible to HBV. 
Transmission of HBV is even more likely to occur with the use of organs from 
HBsAg- positive donors, who are concurrently positive for HBeAg, which is a 
marker of a highly infectious state. 
The technique for handling and preservation of harvested kidney may modify the 
risk of HBV transmission by kidney transplantation. Because the vector of 
transmission seems to be the residual donor blood retained in the harvested 
kidney, rather than the kidney tissue itself, the technique of continuous pulsatile 
perfusion in contrast to preservation on ice could potentially prevent HBV 
transmission by clearing some of the virus and thus reducing the infectious load 
below a certain level, which is probably needed to ensure viral transmission. 
Effect of HBV infection on Post transplantation clinical outcomes in kidney 
transplantation 
The impact of HBV infection on graft and patient survival following kidney 
transplantation has been debated for almost 3 decades. Some studies have shown 
that HBs antigemia in kidney transplant recipient affects adversely the long term 
survival (usually beyond 3 years and in one series only after an even longer follow 
up period, beyond 5 to 15 years post transplantation). However, other investigators 
have observed that HbsAg-positive kidney transplant recipients had significantly 
higher mortality rate than those who were HbsAg negative, regardless of the 
follow up duration (22). The increased risk of developing fatal liver disease is 
believed to be exclusively associated with active viral replication as disclosed by 
the presence of HBeAg and or HBV DNA. Consequently, the wide variation in the 
incidence of fatal liver disease observed across studies could be attributed 
uniquely to differences in the prevalence of HBeAg and or HBV DNA. These 
speculations are supported by the observations that survival in HBsAg-Positive 
kidney transplant recipients with markers of active viral replication was worse 
(although not significantly) than in recipient without these markers. Since there is 
an excellent correlation between HBeAg and serum HBV DNA concentrations, 
HBeAg testing, which is relatively easy to perform, widely available and cheaper, 
has been recommended as a good and reliable marker of viral replication. 
Overall, the increased mortality from liver disease among chronic HBsAg carriers, 
who undergo kidney transplantation, appears to be confined to patients who are 
HBeAg and/ or HBV DNA positive before transplantation. Hence, a policy not to 
transplant these patients but to treat and follow them until they become negative 
for these markers seems reasonable. Such practice would significantly decrease 
the relative risk of fatal post transplantation liver disease. 
Hepatitis C Virus 
Structure of HCV Genome 
HCV is a small 40 to 60 nm virus, which belongs to the Flaviviridae family .It has 
a lipid envelope and a single-stranded RNA viral genome comprising approxi-
mately 9,500 nucleotides. 
Sequence analysis of the viral genome has identified a number of distinct HCV 
variants. A universal system for the nomenclature of hepatitis C viral genotypes 
recognizes six major groups (1 to 6), designated as HCV types .Each major type 
consists of one or more closely related variants, designated as subtypes and named 
a, b, c, etc, in order of discovery. Finally, each subtype includes individual isolates 
(22). 
Epidemiology of HCV infection 
Hepatitis C is the most common chronic blood-borne infection in the United 
States. It accounts for more than 90% of the cases of post transfusion hepatitis, and 
for the majority of all cases of-non-A, non-B hepatitis (NANBH) in the United 
States. 
The prevalence of hepatitis C among kidney transplant recipients is much higher 
than in the general population. As ascertained by a positive anti-HCV test, 
between 9% and 60% of the kidney transplant recipients are infected with the virus, 
with a wide variation among different centers and countries. 
Clinical Course and Natural History of Hepatitis C 
Acute infection typically remains asymptomatic or presents with only mild clinical 
symptoms and therefore is often unrecognized. However, although rare, fatal cases 
of fulminant and sub acute liver failure have been reported. 
Anti HCV antibody production typically begins at 4 weeks, but can be delayed as 
long as 1 year.Their presence is unrelated to the course or outcome of the disease 
(22).In about half of the patients, the disease will take a self-limiting course and 
ALT levels will return to normal. In the other half of the patients, ALT levels will 
remain persistently elevated and a relatively slow, sequential progression from 
acute hepatitis C to chronic HCV infection—chronic hepatitis, cirrhosis and 
hepatocellular carcinoma (HCC) will take place over the years. 
The natural history of acute HCV infection in patients on maintenance dialysis has 
not been well described. A recent prospective study of 19 dialysis patients  with 
acute infection found that after a median follow - up of 3 years, nearly 80% of the 
patients remained viremic, 60% had increased transaminase levels and positive 
HCV RNA tests, with five patients exhibiting chronic active hepatitis on liver 
biopsy, and only four patients (21%) cleared the viral infection (22).The natural 
history of acute HCV infection in kidney transplant recipients remains 
incompletely understood mostly because of the paucity of uniform longitudinal 
observations with available histologic data. Long term studies have revealed 
decreased patient survival late in the second decade following kidney 
transplantation mainly due to liver related and sepsis - related mortality. Cirrhosis 
has been shown to be the most important independent predictor of death after 
kidney transplantation and is believed to be implicated in both liver - related and 
sepsis related mortality. Liver related deaths result by and large from 
decompensated cirrhosis late in the posttransplantation period; and only in 1% to 
5% of the cases are due to fulminant hepatitis or rapidly progressive cholestatic 
liver failure within the first posttransplantation year. 
Immunity 
The immune mechanisms triggered by HCV infection involve humoral and 
cellular responses targeted at multiple determinants of the viral genome. The 
majority of these antibodies are noneutralizing and hence do not provide 
protective immunity. Although neutralizing antibodies to the envelope regions of 
HCV have recently been characterized, their role in protective immunity has not 
been demonstrated. In addition, compelling evidence is now available to 
demonstrate that the cellular responses of the host are inadequate and directly 
contribute to the pathogenicity associated with the viral infection. Consequently, 
in most cases of HCV infection, the immune response fails to control the 
infections, which result in the development of chronic carrier state. Due to lack of 
protective immunity, a number of studies in humans and animals have reported the 
occurrence of reinfection (new infection after the previous infection has cleared) 
with the same or different genotype or super infection (infection with a new 
genotype in the presence of preexisting infection). 
Tests for antibodies to HCV.  
Serologic tests that detect the presence of non neutralizing antibodies to HCV are 
currently the mainstay for the diagnosis of HCV infection. Both enzyme linked 
immunosorbent assays (ELISA) and recombinant immunoblot assays (RIBA) have 
been in use. ELISAs detect antibody to a specific HCV antigen (first generation 
tests) or a combination of antigens(second and third generation tests) in a standard 
ELISA plate and have been used as screening tests. In contrast, RIBAs detect 
antibodies to one or more HCV antigens on a strip that is read visually and by 
virtue of their increased specificity have been considered confirmatory tests. Three 
generation anti- HCV tests have been commercially available for use in clinical 
practice. 
The first generation anti - HCV tests (ELISA1, RIBA1) detect non neutralizing 
antibodies to the C100- 3 (and 5-1-1) protein(s) encoded by the NS3/NS4 region 
of the HCV prototype isolate (i.e., HCV genotype 1a). The performance of these 
anti- HCV tests is compromised by their genotype dependence due to the 
substantial heterogeneity in C100-3 sequences of different HCV genotypes and the 
long “window” period (i.e., the early stage of the infection, when viremia is 
present, but antibody response is not yet manifest) resulting from the delay in 
antibody production to C100-3 antigen in response to HCV infection. These anti 
HCV tests are no longer in use. 
The second - generation anti HCV tests (ELISA2, RIBA2) eliminated some of the 
above shortcomings. ELISA 2 includes c22 antigen form the nucleocapsid region 
and c200, which is a composite of c33 and c100 -3 antigens from the NS3 and 
NS4 region. RIBA2 uses four recombinant HCV antigens (c22, c33, c100 and 5-1-
1). These tests have shown improved performance because first, they have no 
genotype dependence due to the increased number of incorporated antigens with 
highly conserved protein sequences and secondly the “window period” with these 
tests is shorter as the production of antibodies to c22 or c33 proteins precedes by 
at least a month the production of antibodies to c100-3 and seroconversion can be 
detected as early as 4 weeks after exposure. 
The third- generation anti - HCV tests (ELISA3, RIBA3) have further improved 
sensitivity due to incorporation of an additional recombinant antigen from the NS5 
region of the HCV genome, not represented in the previous tests, and an improved 
c33 antigen corresponding to the NS3 region. With the use of these tests, the 
window period has been further reduced and was estimated at the mean of 69.8 
days. Consequently, the third- generation anti - HCV tests have shown better 
performance as compared to the previous two generation anti HCV tests and are 
currently most widely used in clinical practice. 
Kidney transplant recipients who acquire HCV infection perioperatively or in the 
posttransplantation period may demonstrate markedly delayed or even absent 
antibody production to HCV due to profound impairment in the humoral immune 
response associated with the state of iatrogenic immunosuppression .In such cases, 
the kidney transplant recipients will test negative for anti-HCV despite being, 
viremic (23, 24). 
If viral hepatitis is suspected, testing for HCV RNA should be pursued, as this is a 
significantly more sensitive method and the only definitive way to diagnose HCV 
infection in kidney transplant recipients. 
Tests for HCV RNA 
Polymerase chain reaction and branched -chain DNA technology.  
The detection of HCV RNA by reverse transcriptase polymerase chain reaction 
(PCR) has been used as the "gold standard" to identify current HCV infection. 
There are two types of test for HCV RNA presently available - qualitative and 
quantitative assays. 
Qualitative PCR assays: 
 The qualitative PCR assays report the results as presence or absence of HCV 
RNA. These assays are considered the most sensitive tests for the diagnosis of 
HCV infection. However, they are not intended to be used as screening tests for 
detection of HCV infection .The reliability of these tests might be limited by false-
positive and false-negative results. Because PCR is an extremely sensitive test and 
consequently, can detect very low levels of HCV RNA even minor contamination 
can give false positive results .On the other hand, false- negative results may be 
due to imperfect handling and/or storage of blood samples causing a failure to 
detect HCV RNA in up to 40% of samples. Whole blood anti coagulated with 
ethylenediamine tetra acetic acid (EDTA) or with mixed anticoagulants (CPDA-1 
and EDTA) may be stored at up to 25°C (room temperature) for unto 5 days 
without any significant loss in plasma HCV RNA 
Quantitative assays for HCV RNA:  
These tests measure HCV RNA titers. The results are usually expressed in number 
of HCV RNA copies per milliliter of serum. Two different types of tests have been 
developed - quantitative reverse transcriptase PCR (RT-PCR) assays and branched 
-chain DNA (bDNA) assays. Several commercial quantitative HCV RNA assays 
are presently available. The lower limit of detection for currently used bDNA 
assays is 200,000 RNA genome equivalents/mL, while the lower limit of detection 
for the RT-PCR method is fewer than 100 RNA genome equivalents/mL. Thus, 
theoretically, the quantitative RT-PCR assay is three orders of magnitude more 
sensitive than the bDNA assay. 
Significant shortcomings of the PCR assays are their labor-intensive performance, 
lack of standardization and wide variations in sensitivity and specificity. By 
comparison, the bDNA assays are automated, simpler to perform, and more 
reproducible, but less sensitive than the quantitative PCR tests. In clinical practice, 
quantitative tests for HCV RNA should not be  used as an initial diagnostic tool 
for HCV infection, but should be reserved for pretreatment evaluation and 
monitoring patient response to antiviral therapies. Because of the great variability 
in sensitivity and lack of standardization across assays and laboratories, when a 
patient is tested repeatedly, particularly when monitoring the response to antiviral 
treatment it is critical to use the same tests and the same laboratory where previous 
testing was performed. 
Tests for HCV Genotypes 
Since the universal system for classification and nomenclature of HCV genotypes 
is based on nucleotide sequence comparisons of the NS5 region of the viral 
genome, the nucleic acid sequencing of this region is generally considered to be 
the gold standard for the precise identification of the viral type, subtype or isolate. 
Other more practical methods for identifying HCV genotypes include PCR using 
subtype specific primers, restriction fragment length polymorphism (RFLP) 
analysis, cleavage fragment length polymorphism (CFLP) technology and line 
probe assay. An ELISA that detects antibodies to serotype - specific 
immunodominant epitopes from the NS4 region of the HCV genome and novel 
RIBAs has been also developed. 
HCV genotyping is mostly used as a tool for research or epidemiological 
investigations tracing the source of infection. HCV genotype testing is 
unnecessary for the diagnosis of HCV infection, but may potentially be useful in 
clinical practice to assist in tailoring antiviral therapy to the individual patient’s 
HCV genotype. 
Difficulties in interpreting tests for HCV infection 
 Anti- HCV positive, but HCV RNA negative patients 
Despite the fact that the anti - HCV tests currently licensed for clinical use detect 
nonneutralizing antibodies to recombinant HCV antigens, the presence of anti - 
HCV does not always imply the presence of HCV RNA in the serum. For 
example, HCV RNA has been detected in only 52% to 93% of anti - HCV positive 
dialysis patients. Several possibilities could account for the presence of anti HCV 
in the absence of HCV RNA. First, HCV may be sequestered at sites other than 
the blood stream, such as the liver or peripheral blood mononuclear cells. Second, 
viremia could be intermittent and therefore, HCV RNA may not be present in the 
plasma at the time of testing. Indeed, 35% of HCV infected dialysis patients 
demonstrated fluctuating pattern of viremia with virus - free intervals. Third, the 
number of copies of HCV RNA may be below the limit of detection. Fourth, 
antibody to HCV may persist even after the viral RNA has disappeared. In this 
situation, anti HCV positive, but HCV RNA negative patients might represent a 
group that had been infected with the virus, but no longer harbor it, and for this 
reason are no longer infective. Fifth, false - positive results can occur due non-
specific reactions, a problem, which has been largely resolved in the current tests. 
 
Anti HCV negative, but HCV RNA positive patients. 
  More than 90% of non immunosuppressed individuals with HCV infection, 
but only around 85% of the HCV infected kidney transplant recipients test positive 
for anti - HCV. In the rest of the cases, HCV RNA is present in the absence of anti 
- HCV. The following possible scenarios can account of the presence of HCV 
RNA in HCV - infected individuals who are anti -HCV negative; First, the anti 
HCV test may not be sensitive enough to detect existing anti HCV antibody, either 
because of the low titer of antibody or because the antigen used in the assay 
system cannot detect the serum antibody response to the particular genotype. 
Second, various diseases or pharmacological immunosuppression could suppress 
or modify the anti -HCV response. For example, the state of iatrogenic 
immunosuppression in HCV infected kidney transplant recipients often results in 
delayed or even absent anti - HCV production. Consequently in one study, 15% of 
the HCV RNA positive kidney transplant recipient tested negative for anti HCV 
by ELISA 2. Third, the patient may be in the “Window” period between infection 
and seroconversion. Further, after anti - HCV antibody has persisted for a certain 
period of time, it can disappear despite the persistence of HCV RNA. 
In addition, HCV RNA has been detected in the peripheral blood mononuclear 
cells (PBMCs) from hemodialysis patients who are both anti HCV and HCV RNA 
negative. The HCV RNA in these PHMCs could severe as a viral reservoir and 
further frustrate efforts to identify HCV infection in ESRD patients. 
Relationship among serum ALT levels, HCV infection and liver disease.  
Studies have consistently demonstrated that among patients on kidney replacement 
therapy, serum ALT levels are poor predictor of HCV induced liver disease and 
when used alone have limited diagnostic value. Among HCV infected dialysis 
patients, elevations in serum ALT levels have been detected only in 4% to 67% of 
those who have antibodies directed against HCV, in 12% to 31% of those who are 
HCV RNA positive and in 33% of those with biopsy proven hepatitis. Likewise, 
among HCV infected kidney transplant recipients, persistently abnormal or 
intermittently abnormal serum transaminase levels have been reported in only 23% 
and 35% of the cases, respectively, while persistently normal serum transaminase 
levels have been found in 42%. Among HCV RNA positive transplant recipients, 
biochemical evidence of liver disease has been found in only 42% to 52% of the 
cases. In addition, there has been no reported association between HCV genotype 
and liver enzyme activity. 
Normal ALT levels cannot exclude the presence of liver disease for the following 
reasons: First, chronic HCV infection has a clinical course featured by constant 
fluctuations in ALT serum levels presenting with multiple peaks and troughs that 
are usually within normal range. Second, HCV infection is not always associated 
with chronic liver disease. There is clear evidence of the existence of HCV healthy 
carrier status following kidney transplantation. For example, in one study, about 
20% of the kidney transplant recipients with chronic HCV infection were 
considered to be healthy HCV carriers based on evidence of ongoing active HCV 
infection (as demonstrated by the presence of HCV RNA in consecutive serum 
samples), consistently normal serum ALT levels on successive tests and normal 
histology on liver biopsy performed after at least 2-year follow-up .It is speculated 
that in these cases, viral replication probably occurs at extra-hepatic sites in the 
absence of any apparent liver involvement. Third, anti-HCV may be the remnant 
of a past infection. Fourth, dialysis patients have depressed serum ALT levels at 
baseline and ALT elevations from baseline values might be unrecognized if they 
remain within   the   generally accepted   normal   range. Furthermore, some 
authors have suggested that the reference range for normal ALT values should be 
adjusted for dialysis patients . 
Since in most kidney transplant recipients, HCV infection is acquired prior to 
transplantation and in the majority of cases while on dialysis, understanding the 
sensitivity, the specificity and the predictive values of an elevated ALT level for 
the diagnosis of HCV infection in dialysis patients is important for the 
comprehensive evaluation of the kidney transplant candidate. A newly elevated 
ALT level was found to be sensitive (83% sensitivity) and specific (90% speci-
ficity) for the diagnosis of acute HCV infection, but had a low positive predictive 
value, only 4%. For chronic HCV infection, a newly elevated ALT level had a low 
sensitivity (21%), but a good specificity (91%) and again a low positive predictive 
value (16%). The negative predictive value of a newly elevated ALT level was 
99% for acute HCV infection and 94% for chronic HCV infection. These data 
provide additional evidence that an elevated ALT level is an ineffective method 
for screening for HCV infection in dialysis patients, many of whom might become 
kidney transplant candidates at some point. 
Liver Histology 
Liver biopsy is the gold standard for confirming the diagnosis of HCV-induced 
liver disease and the only means of precisely assessing the degree of liver 
involvement. Liver histology is a useful prognostic tool for the progression of 
chronic liver disease after kidney transplantation (12). 
A large diversity of morphological lesions with considerable- differences in their 
severity among different studies has been observed on liver biopsies of HCV-
infected kidney transplant recipients. 
The typical histological lesions found on liver biopsies of HCV infected kidney 
transplant recipients include minimal changes, persistent chronic hepatitis, chronic 
active hepatitis and liver cirrhosis. Although rarely, hepatocellular carcinoma, 
nodular regenerative hyperplasia, fibrosing cholestatic hepatitis, vanishing bile 
duct syndrome and other nonspecific lesions have been observed. Serial biopsies, 
usually performed on patients with clinical and/or biochemical evidence of 
progressive liver disease or with histological findings on initial liver biopsy 
revealing more advanced stages of liver impairment, have commonly 
demonstrated histological progression of liver disease. 
A Meta analysis of 17 published studies, including a total of 560 HCV-infected 
kidney transplant recipients who underwent liver biopsy reveal that the patients 
had significant differences in their clinical presentation and laboratory data. 
Furthermore, the criteria for performing liver biopsy were not uniform. In fact, in 
the over whelming majority of instances the liver biopsy was prompted by the 
presence of clinically overt severe liver disease or abnormal liver biochemistry. 
Over all, chronic hepatitis and liver cirrhosis were present in 70% of the patients 
while only 21% had normal histology or minimal changes. These findings of 
severe liver lesions in a significant percentage of the HCV infected kidney 
transplant recipients should be interpreted with caution since in none of these 
studies liver biopsy was performed routinely (24, 25).  
The severity of liver histology in kidney transplant candidates with HCV infection 
largely influences the final decision whether to proceed with kidney 
transplantation.  HCV infected kidney transplant candidate whose liver histology 
reveals chronic persistent hepatitis or mild active hepatitis may be accepted for 
kidney transplantation, without reservations. It is still debatable whether HCV 
infected patients with biopsy - proven advanced chronic active hepatitis or early 
cirrhosis should be considered for kidney transplantation or be advised to continue 
on dialysis. Because liver disease in immunosuppressed patients may often take a 
progressive course, many nephrologists are reluctant to offer kidney 
transplantation to this group of patients. Patients with advanced cirrhosis may be 
considered for combined liver and kidney transplantation. However, current date 
are insufficient to precisely determine which is the best option for the ESRD 
patient with HCV infection, and the recommendations discussed above are, to a 
large extent, opinion based rather than evidence based and adopted from studies in 
the general population. Therefore, any decision regarding kidney transplantation 
should be made after considering the effect of immunosuppression on the natural 
course of HCV that may lead to enhanced viral replication and possible 
exacerbation of liver disease, the life expectancy of the patients, the quality of life 
on dialysis, the expected quality of life after transplantation and the patient’s 
informed choice between dialysis or transplantation. Finally, liver histology has 
been useful as a predictor of patient response to IFNa therapy and could serve for 
patient selection of antiviral treatment. 
Effects of pretransplantation anti - HCV status on posttranplantation clinical 
outcomes 
Pretransplantation anti - HCV is associated with an increased risk of 
posttransplantation liver disease, which is present in 19% to 64% of anti - HCV 
positive recipients as compared to 1% to 30% among anti HCV negative recipient 
(24).Studies from the New England Organ Bank have shown that the relative risk 
of posttransplantation liver disease among recipients with anti HCV prior to 
transplantation was 5.0.Among patients with pretransplantation HCV RNA in the 
serum, kidney transplantation was associated with a 1.8 to 30.3-fold increase in 
viral titer, suggesting proliferation of HCV in the posttranplantation period. 
However, among patients with HCV RNA detected in the serum, the titer of HCV 
RNA did not differ between patients with and without posttransplantation liver 
disease. 
Although pretransplantation anti - HCV is consistently associated with an 
increased risk of post transplantation liver disease; reports on post transplantation 
patient survival have been controversial. Some studies have failed to detect 
significant differences in patient survival between recipients with and without anti 
HCV prior to kidney transplantation. 
Another study has found a lower 8-year patient survival among the anti HCV 
positive recipients compared to HCV negative controls. Results from the New 
England Organ Bank study revealed that recipients with pretransplantation anti - 
HCV had a 3.3 fold higher risk of death (95% confidence intervals of 1.4 to 7.9) 
and a 9.9 fold higher risk of death due to sepsis. 
The leading cause of death among anti - HCV positive recipients was infection 
rather than liver failure (25). 
A retrospective study from France evaluated almost 500 hepatitis B virus negative 
patients with kidney failure who subsequently under went kidney transplantation. 
Survival and the causes of death in the post transplantation period were compared 
between anti - HCV positive and anti HCV negative recipients. Multivariate 
analysis found that HCV infection was associated with a significant increase in the 
mortality rate (odds ratio of 2.8) which was principally due to liver disease and 
sepsis (30). 
Similarly, a case control study including 216 HCV infected kidney transplant 
recipients demonstrated that HCV infected recipients had significantly lower ten 
year graft and patient survival than their matched controls (29). 
In another study presenting a large histological cohort analysis of 33,479 kidney 
transplant recipients in the USRDS from July 1, 1994 to June 30, 1997, kidney 
transplant recipients who were anti - HCV positive at the time of transplantation 
had significantly higher total all cause, unadjusted mortality (13.1%) than kidney 
transplant recipients who were anti HCV negative at the time of transplantation 
(8.5%). In Cox regression, mortality was higher for kidney transplant recipient 
who were anti HCV positive at the time of transplantation. The differences among 
studies in patient survival could be due to several factors: (a) differences in study 
design, such as selection of patients, and length and completeness of follow-up; 
(b) virus and test factors, such as sensitivity and specificity of anti-HCV test, 
prevalence of serum HCV RNA, HCV genotype of infecting virus and single or 
mixed infection; and  
(c) the presence and severity of pretransplantation liver disease, HLA matching 
and immunosuppression protocols. Indeed, the severity of pretransplantation liver 
disease, particularly the presence of cirrhosis, has been shown to be an important 
predictor of adverse post transplantation outcomes. 
In the absence of definite data demonstrating worse out comes after kidney 
transplantation, anti HCV positive status alone should not be considered a 
contraindication for kidney transplantation and anti HCV positive ESRD patients 
should be allowed to make an informed choice between dialysis or transplantation. 
However, because the histological severity of liver damage is a strong predictor of 
liver failure and death after transplantation and because dialysis patients and 
transplant recipients can have histological evidence of liver disease in the absence 
of increase ALT levels, there may be merit in a policy of performing liver biopsies 
on anti HCV positive patients awaiting kidney transplantation. In patients with 
histological evidence of liver disease, the decision to proceed with kidney 
transplantation should be made cautiously, after taking into consideration, the 
influence of immunosuppression on viral replication and the possibility of liver 
disease exacerbation. 
 
POST TRANSPLANT DIABETES MELLITUS IN RENAL TRANSPLANT 
RECIPIENTS 
 
Diabetes mellitus was described as a complication of kidney transplantation over 
30 years ago. The reported incidence of PTDM range from 2% to53%, reflecting 
wide variations in the definition of this disorder (32).The most commonly used 
definition of PTDM is the requirement for insulin therapy for an arbitrarily 
minimum period of time (30 days).Such a definition underestimates the prevalence 
of PTDM because it excludes patients treated with oral hypoglycemic agents and 
those with impaired glucose tolerance. 
Patients are at greatest risk of developing PTDM during the first 6 months 
following kidney transplantation. Compared to non-diabetic renal transplant 
recipients, those with PTDM exhibit decreased graft survival at 4 years (54% Vs 
82%) Roth et al. 
PATHOGENESIS OF PTDM 
The incremental incidence of diabetes mellitus in renal transplant recipients is path 
physiologically linked most closely to immunosuppressive therapy with 
corticosteroids and/or Calcineurin inhibitors. The absence of treatment with 
Antiproliferative agents (MMF/Azathioprine) was associated with increased risk 
of PTDM.  
 
RISK FACTORS OF PTDM 
 1. ETHNICITY 
                        African –American ethnicity is one of the strongest risk factor. 
 2. AGE 
                        Age>40 years 
 3. BODY WEIGHT  
The risk of developing PTDM increases by a factor of 1.4 for every 10 kg increase 
in body weight over 60 kg. 
  4. HEPATITIS C 
              There is a strong association between Hepatitis C virus infection and 
development of diabetes mellitus after either kidney or liver transplantation (33).    
Analysis by Kasiske et al shows that the relative risk factors for PTDM in order of 
importance are 
                      1. Age>60 years  
          2. Obesity (BMI>30) 
          3. African-American ethnicity. 
          4. Hepatitis C virus antibodies.  
 
 
 
 
 
MATERIALS AND METHODS 
This study is a prospective study conducted in the department of nephrology 
during the time period from august 2007 to December 2009. Renal transplant 
recipients with clinical or biochemical evidence of acute hepatic dysfunction were 
included in the study.  
A detailed diagnostic workup done was performed to establish the etiology of 
hepatic dysfunction. Patients were analyzed for pretransplant liver status (which 
included Liver Function Tests, viral serology, vaccination status, risk factors for 
liver disease). All the diagnostic work up done for liver dysfunction in the post 
transplant period were noted for detailed analysis (which included LFT, 
ultrasonogram of Abdomen, viral serology, UGI scopy,Renal biopsy, liver biopsy 
etc.).  
Outcome was assessed in terms of resolution of liver dysfunction, allograft 
function and mortality at defined time periods (at the time of presentation, 3 and 6 
months after presentation). 
 
 
 
 
 
 
DEFINITIONS:  
ACUTE LIVER DYSFUNCTION: 
An episode of liver dysfunction was termed "acute" if the results of liver tests 
returned entirely to normal in less than 6 months or the patient died within 3 
months of its onset. 
 
CHRONIC LIVER DYSFUNCTION: 
The liver disease was considered "chronic" if the patient manifested persistent lab 
abnormal liver test results for longer than 6 months or died after at least 3 months 
of unremitting severe disease. 
 
HEPATITIS B VIRUS INFECTION:  
The presence of HBV infection was defined by the presence in the recipient of 
positive HBsAg. 
 
HEPATITIS C VIRUS INFECTION:  
The presence of HCV infection was defined by the presence in the recipient of 
positive anti-HCV antibodies.  
 
 
COMBINATION OF HEPATITIS B AND HEPATITIS C INFECTION:  
This was defined by the concomitant presence of both positive HBsAg and 
positive anti-HCV antibodies. 
 
CMV INFECTION: 
 This was defined by the presence of PP65 antigenemia more than 2/105 
infected leucocytes studied. 
 
ATTRIBUTION OF CAUSE 
An episode of liver disease was considered to be the consequence of hepatitis B 
virus infection if the onset of the liver disease coincided with the appearance of 
HBsAg in the patient's serum or if the initial manifestations were followed within 
2 months by the development of circulating anti-HBc either alone or in company 
with anti-HBs.  
Cytomegalovirus infection was incriminated if seroconversion to cytomegalovirus 
occurred within 1 month of the onset of the liver disease and if there was no other 
reasonable etiologic explanation apparent. The diagnosis was strengthened by the 
occurrence of a typical febrile illness, or the finding of characteristic intranuclear 
inclusions on microscopic examination of such a biopsy. 
The diagnosis of a drug-related disease required the temporal concurrence of the 
hepatic dysfunction with the initiation of drug therapy (or an increment in dosage) 
or the resolution of the episode with interruption (or a decrease in the dosage) of 
the agent under suspicion. A drug-related cause was only accepted in the absence 
of any reasonable alternative cause. 
CLINICAL AND VIROLOGICAL STUDIES: 
 HBsAg and anti- HCV serology were done by ELISA. 
           CMV infection was diagnosed using PP65 antigenemia assay. 
            Renal biopsy was done in patients with allograft dysfunction. 
            Liver biopsy was done in selected cases. 
 
STATISTICAL ANALYSIS 
The x2 test was used to compare qualitative values. Parametric tests (Student’s t-
test and Fisher’s exact test) and nonparametric tests (Mann-Whitney test) were 
used to compare quantitative variables. 6 months graft and patient survival were 
estimated by the Kaplan-Meier method and compared by log-rank test. Prognostic 
values of HBV and HCV infections were assessed by the respective survivals at 6 
months estimated by Kaplan-Meier method and compared by log-rank test. The 
independent prognostic values of HBV and HCV infections were assessed by the 
proportional hazard regression. 
 
 
 
RESULTS 
A total of 35 renal allograft recipients with acute liver dysfunction were studied. 
The mean age of the study population was 31.5 yrs (youngest being 17 yrs and the 
oldest being 55 yrs).  
TABLE 1: AGE DISTRIBUTION OF THE PATIENTS 
 
The male female ratio in this study was 6:1 (male – 30; female – 5).  
TABLE 2: SEX DISTRIBUTION OF THE PATIENTS 
Sex  Male  Female  Total  
No. of patients 30 5 35 
 
Mean duration of presentation with acute liver dysfunction following 
transplantation was 18.6 months (Range: 1 month – 180 months). Patients who 
were seropositive for hepatotropic viruses presented earlier (9.5 months) with 
hepatic dysfunction when compared to those who were seronegative (20.5 
months). (P-value – 0.05). This observation was statistically significant. 
 
 
Age  ( Yrs) < 20 21 – 40 > 40 Total  
No. of  patients 3 28 4 35 
TABLE 3: INFLUENCE OF BLOOD TRANSFUSION ON POST 
TRANSPLANT HEPATOTROPIC VIRAL INFECTION 
Category of 
patients 
Patients with 
viral infection
Patients 
without viral 
infection 
Total patients Percentage 
with viral 
infection 
With blood 
transfusion 
7 2 9 78 
Without 
blood 
transfusion 
13 13 26 50 
                                                                                 (P-value – 0.005) 
Out of 9 patients who received blood transfusion 7(78%) became seropositive for 
hepatotropic viruses, whereas 13(50%) out of 26 patients who did not receive 
blood transfusion became seropositive. Correlation between the development of 
post transplant hepatotropic viral infection and pre transplant blood transfusion 
was statistically significant. 
TABLE 4: INFLUENCE OF VACCINATION ON POST TRANSPLANT HBV 
INFECTION 
HBV 
vaccination 
Patients with 
HBV 
infection 
Patients 
without HBV 
infection 
Total patients Percentage 
with HBV 
infection 
Complete  3 17 20 15 
Incomplete  2 13 15 13 
                                                                          (P-value – 0.13) 
 
20 patients completed full course of HBV vaccination but 3 of them developed 
HBV infection. Of the 15 patients who had incomplete vaccination, 2 acquired 
HBV infection. No statistical significance was noted in the incidence of HBV 
infection between patients who received a full course of HBV vaccine and those 
who had not. 
TABLE 5: ETIOLOGY OF LIVER DYSFUNCTION 
Etiology  No. of  patients Percent  
Viral 20 57 
Drug  12 34 
Bile duct obstruction 1 3 
Acute Pancreatitis  1 3 
Unknown etiology 1 3 
Total  35 100 
 
  The most common cause of acute liver dysfunction was viral infection ,20 
patients(57%) followed by drugs,12 patients(34%).1 case each of Acute 
pancreatitis and Gall stone with common bile duct stricture were seen. Etiology 
could not be ascertained in one patient.  
 
 
 
 
TABLE 6:  VIRAL ETIOLOGY OF LIVER DYSFUNCTION 
Viral etiology No. of patients Percent  
HCV 9 45 
CMV 6 30 
HBV 3 15 
HBV& HCV 1 5 
HBV& CMV 1 5 
Total  20 100 
 
HCV was the most common among viral infections (9/20)-45%.CMV accounted 
for 6 cases (30%).HBV was seen in 3 patients (15%).Combined HBV/HCV was 
seen in one patient, while one had combined HBV/CMV infection. Liver biopsy 
could be done only in 2 of the patients due to logistic reasons; with one showing 
features of cirrhosis and another had features of cholestatic hepatitis. 
TABLE 7: PRESENTING COMPLAINTS OF PATIENTS 
Clinical 
parameters 
No. of 
patients
Percentage 
Vomiting 22 63 
Jaundice  22 63 
Pruritus 5 14 
Encephalopathy 1 3 
Ascites 2 6 
GI bleed 1 3 
Abdominal 
pain 
6 18 
Total  35  
 TABLE 8: DISTRIBUTION OF SERUM BILIRUBIN LEVELS 
Bilirubin  
range 
(mg/dl) 
< 3 
 
4 - 6 7 – 9 > 10 
T.Bilirubin 22 7 1 5 
D.Bilirubin 28 1 3 3 
 
Jaundice was the predominant symptom noted, (63%). The mean Bilirubin level 
was 5mg/dl (range:1.0-40mg/dl).Conjugated hyper bilirubinemia was 
predominantly observed.  
 
TABLE 9: PTDM AND VIRAL ASSOCIATION 
 
PTDM was seen in 20 %( 7) of the patients. Viral association was noted in 5 of 
those who had PTDM. HCV infection was seen in 2 patients with PTDM. No 
statistically significant correlation was seen between viral infections and PTDM. 
Viral 
serology 
status 
HCV HBV HBV&HCV CMV Sero 
negative  
Total 
Patients with 
PTDM 
2 1 1 1 2 7 
p-value  0.13 0.2 0.2 0.2 0.13  
TABLE 10: CAUSE OF LEUKOPENIA 
Cause of 
leucopenia 
Drug 
induced 
CMV CMV 
& 
HBV 
Total  
No. of 
patients 
7 6 1 14 
 
14 patients had leucopenia, 50% (7) were drug related. CMV infection accounted 
for 6 cases. 
TABLE 11: OUTCOME OF HEPATIC DYSFUNCTION 
 
 
 
Liver dysfunction 
completely normalized 
in majority of patients (83%).4 patients had persistent liver dysfunction at the end 
of 6 month follow up. One of the 2 patients who developed DCLD succumbed to 
his illness. 
 
 
 
 
Liver dysfunction 
Outcome  
Improved  29 
persistent 4 
DCLD 2 
Total  35 
TABLE12: RENAL ALLOGRAFT SURVIVAL IN VARIOUS GROUPS 
Viral serology 
status 
HCV CMV HBV HBV & 
CMV 
HBV & 
HCV 
Sero 
negative 
Total
No. of  patients 
with renal  graft 
failure  
3 2 1 0 1 3 10 
No. of patients 
without graft 
failure 
6 4 2 1 0 12 25 
Total  9 6 3 1 1 15 35 
p-value  0.18 0.22 0.33 0.5  0.22  
. 
Chronic allograft renal failure was seen in 10 of 35 patients. All had CAN 
histology in renal biopsy. 3 patients had HCV infection, while 3 were seronegative 
.1 patient with HBV infection and 1 with HBV/HCV developed allograft failure.2 
cases of allograft renal failure were associated with CMV infection. Viral infection 
and renal allograft failure had no statistically significant correlation in our study. 
TABLE 13: PATIENT OUTCOME IN THE STUDY 
Patient outcome survived 29 
expired 6 
Total 35 
 
6 patients (17%) died during the study period. Sepsis was the cause of mortality in 
5 patients.  
 
TABLE14: PATIENT SURVIVAL AND VIRAL SEROLOGY STATUS 
Viral serology 
status 
HCV CMV HBV HBV & 
CMV 
HBV & 
HCV 
Sero 
negative 
Total
No. expired 1 1 0 0 0 4 6 
No. survived 8 5 3 1 1 11 29 
Total   9 6 3 1 1 15 35 
p-value 0.21 0.31 0.35 0.34 0.33 0.2  
 
Only one out of the 9 patients with post transplant HCV infection died, during the 
six month follow up period.No deaths were noted in the HBV infected group, 
while 4 out of the 15 seronegative patients’ expired.One patient each with 
combined HBV/HCV & HBV/CMV survived. 10% of those who had hepatotropic 
viral infections died, while 27% of deaths were due to non viral causes. Viral 
infection and patient survival had no statistically significant correlation in our 
study. 
 
 
 
 
 
 
 
 TABLE15: PATIENT SURVIVAL AT DEFINED TIME INTERVALS IN 
DIFFERENT PATIENT GROUPS 
Viral serology 
status 
HCV HBV CMV Sero 
negative 
Survival at 0 
month 
9 3 6 15 
Survival at 3 
months 
9 3 5 12 
Survival at 6 
months 
8 3 5 11 
 
3 seronegative patients were dead by 3 months due to sepsis; while 1 patient with 
CMV died during the same time period. Only 2 deaths were noted during the next 
3 months. 
 
 
 
 
 
 
 
 
DISCUSSION 
35 renal allograft recipients admitted with acute liver dysfunction during the time 
period from August 2007 to December 2009 were studied. The mean age of the 
study population was 31.5 yrs (youngest being 17 yrs and the oldest being 55 yrs). 
The male female ratio in this study was 6:1 (male– 30; female– 5).  
Mean duration of presentation with acute liver dysfunction following 
transplantation was 18.6 months (Range: 1 month – 180 months).  
According to Ware et al, in about 80% of the patients with liver disease the 
clinical symptoms and or laboratory abnormalities occur within 6 months (peak 
between 8 and 12 weeks) from the date of transplantation (2, 13). 
This might be due to the late presentation of hepatotropic virus induced liver 
dysfunction in our study. 
Patients who were seropositive for hepatotropic viruses presented earlier (9.5 
months) with hepatic dysfunction when compared to those who were seronegative 
(20.5 months).  
Out of 9 patients who received blood transfusion 7(78%) became seropositive for 
hepatotropic viruses, (2/7 were HCV positive & 2/7 were HBV positive, rest were 
CMV positive) whereas 13(50%) out of 26 patients who did not receive blood 
transfusion became seropositive.  
 
Hepatitis C is the most common chronic blood-borne infection in the United 
States. It accounts for more than 90% of the cases of post transfusion hepatitis, and 
for the majority of all cases of-non-A, non-B hepatitis (NANBH) in the United 
States (6). 
Kidney transplant recipients who acquire HCV infection perioperatively or in the 
post transplantation period may demonstrate markedly delayed or even absent 
antibody production to HCV due to profound impairment in the humoral immune 
response associated with the state of iatrogenic immunosuppression .In such cases, 
the kidney transplant recipients will test negative for anti-HCV despite being, 
viremic (23, 24). 
If viral hepatitis is suspected, testing for HCV RNA should be pursued, as this is a 
significantly more sensitive method and the only definitive way to diagnose HCV 
infection in kidney transplant recipients (24). Many patients with HCV infection 
could have been missed in the study since HCV RNA was not done in all cases 
due to cost constraints. 
20 patients completed full course of HBV vaccination but 3 of them developed 
HBV infection. Of the 15 patients who had incomplete vaccination, 2 acquired 
HBV infection. 
The prevalence of HBsAg among kidney transplant recipients decreased 
significantly from 24.2% before 1982 to 9.1% after 1982, when routine HBV 
vaccination of dialysis patients was implemented (8). 
Decreased protective effect of HBV vaccination in our study may be due to 
decreased mounting of immune response to the vaccine, which is generally seen in 
immunocompromised patients. 
The most common cause of acute liver dysfunction seen in our study was viral 
infection, 20 patients(57%) followed by drugs,12 patients(34%).1 case each of 
Acute pancreatitis and Gall stone with common bile duct stricture were seen. 
Etiology could not be ascertained in one patient.  
HCV was the most common among viral infections (9/20)-45%.CMV accounted 
for 6 cases (30%).HBV was seen in 3 patients (15%).Combined HBV/HCV was 
seen in one patient, while one had combined HBV/CMV infection. 
The potential causes of liver disease in the immunosuppressed host are legion. 
Chief consideration must be given, however, to viral infections and drug reactions. 
Hepatitis B virus infection has been the major culprit in many of the previously 
reported experiences with liver disease occurring in patients after renal 
transplantation. But a study by Ware et al, found that HCV accounted for most of 
the post renal transplant liver dysfunction (6). 
Azathioprine, an immunosuppressive agent can induce dose - dependent liver 
injury (6). The pathogenesis of azathioprine hepatotoxicity, although incompletely 
understood, seems to involve direct injury to hepatic endothelial cells, hepatocytes 
and intralobular ducts (17). Biochemical abnormalities are consistent with 
cholestatic pattern of liver injury (i.e. direct bilirubinemia with increased serum 
levels of alkaline phosphate and gamma - glutamyltranspeptidase). These 
abnormalities, commonly improve or resolve with a decrease in azathioprine dose 
or with its discontinuation, but recur in about 50% of the patients if the drug is 
reinstituted.  
All our patients with drug induced hepatitis presented with cholestatic jaundice 
which resolved completely on withdrawal of drug. 
One patient presented with severe jaundice, 4 months post renal transplant (Total 
Bilirubin- 40mg/dl; direct-22mg/dl). Suspecting azathioprine induced jaundice, the 
drug was stopped. Bilirubin levels decreased to 10 mg/dl. Since he had persistent 
jaundice even after 2 months with a negative serology for all known hepatotropic 
viruses, a liver biopsy was performed. It was reported as cholestatic hepatitis 
possibly drug induced. 2 months later patient developed worsening jaundice with 
massive hematemesis and died.  
Another patient with jaundice, a 22 yr old female renal transplant recipient of 1yr 
duration, on evaluation was found to have gall stones and CBD stricture. She 
underwent ERC with stenting followed later by laparoscopic cholecystectomy. She 
had complete resolution of jaundice following the procedure. This was the only 
surgically correctable cause of jaundice in our case series. 
CsA-induced liver disease commonly presents clinically as acute hepatic injury, 
mainly of cholestatic type and occurs early in the post transplantation period, 
usually within the first 3 months (19). There is a possible association of CsA with 
biliary tract disease. (Gall stone disease). The most common biochemical abnor-
mality is conjugated hyperbilirubinemia alone, or in association with minimal 
elevation in liver enzymes. The increase in serum bilirubin appears to be dose-
dependent and reversible after dose reduction or discontinuation of the drug. 
Jaundice was the predominant symptom noted, (63%) in our study population. In 
patients with post transplant liver disease, complaints are mainly constitutional, 
vague or mild and not infrequently, the patient can be asymptomatic. Physical 
findings characteristic of liver disease, such as jaundice, hepatosplenomegaly, 
spiders or any other symptoms of portal hypertension are usually absent unless the 
liver disease progresses to very advanced stages (4, 6, 8). 
Evidence of DCLD like Esophageal Varices was noted only in two of the patients. 
The mean Bilirubin level was 5mg/dl (range:1.0-40mg/dl).Conjugated hyper 
bilirubinemia was predominantly observed.  
PTDM was seen in 20 %( 7) of the patients. Viral association was noted in 5 of 
those who had PTDM. All patients were younger than 60 years. Only one patient 
with HBV infection had a family history of diabetes.HCV infection was observed 
in two of the patients, while one had combined HBV/HCV infection. Two patients 
did not test positive for any of the viruses nor did they have a family history.CMV 
accounted for a single case of PTDM.The incidence of PTDM in the study 
population was 19.6%.  
The reported incidence of PTDM range from 2% to53%, reflecting wide variations 
in the definition of this disorder (32).14 patients had leucopenia, 50 %,(7 patients) 
were drug related.  CMV infection, (6 patients) was the second most common 
cause in this study. The cause for leukopenia could not be ascertained in one 
patient. 
Liver dysfunction completely normalized in majority of patients (83%). 4 patients 
had persistent liver dysfunction. Of the 4 patients who had persistent liver 
dysfunction, 2 were seronegative, 1 had CMV, and the other HCV.All 4 patients 
died due to sepsis.2 patients developed DCLD during follow up. Only one patient 
with DCLD was positive for HBV infection. One of the 2 patients who developed 
DCLD succumbed to his illness. 
Chronic allograft renal failure was seen in 10 of 35 patients. All had CAN 
histology in renal biopsy. 3 patients had HCV infection, while 3 were seronegative 
.1 patient with HBV infection and 1 with HBV/HCV developed allograft failure. 2 
cases of allograft renal failure were associated with CMV infection.       
According to a Spanish study by Morales et al (25), HBV infection in the 
recipients did not influence graft and patient survival. However, HCV infection in 
the recipient was associated with lower graft and patient survival. Only those 
patients who had a functioning renal allograft after one year were included in the 
study. The study period was for 8 yrs. 
In a study by Mathurin et al (22), it was observed that (1) age at transplantation, 
year of transplantation, and HBV and HCV were independent prognostic factors in 
10-year graft and patient survival; (2) comparison between infected patients and 
their matched controls confirmed the deleterious impact of HBV and HCV; and 
(3) there was a significant increase of liver-related mortality in infected patients 
(25%). 
 
 
In our study, only one out of the 9 patients with post transplant HCV infection 
died, during the six month follow up period.No deaths were noted in the HBV 
infected group, while 4 out of the 15 seronegative patients expired.One patient 
each with combined HBV/HCV & HBV/CMV survived. 10% of those who had 
hepatotropic viral infections died, while 27% of deaths were due to non viral 
causes.  
3 seronegative patients were dead by 3 months due to sepsis; while 1 patient with 
CMV died during the same time period. Only 2 deaths were noted during the next 
3 months. 
HBV & HCV did not have any impact on patient and graft survival in the study. 
This was in contrast to the previous studies. The discrepancy in the results could 
be attributed to the short follow up period in this study. Many patients with HCV 
infection could have been missed in the study since HCV RNA was not done in all 
cases.  
It is noteworthy that hepatic disease develops late after transplantation; therefore 
duration of the follow-up period is critical in the assessment of HCV effect on 
survival. The deleterious effect of HCV would occur after a long-term period 
following the transplantation. 
 
 
 
 
 CONCLUSIONS 
Viral infections were found to be the commonest cause of hepatic dysfunction 
followed by immunosuppressive medications. 
Pre transplant blood transfusion contributed significantly to post transplant 
hepatotropic viral infection. 
Occurrence of post renal transplant hepatic dysfunction was earlier in patients with 
Pre transplant hepatitis virus infection. 
Hepatitis C was the most common viral infection observed. 
Cholestatic jaundice was the predominant clinical presentation. 
Hepatitis B and C virus infections did not have any impact on patient and graft 
survival. 
Commonest cause of mortality observed was sepsis. 
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PROFORMA FOR STUDY OF LIVER DISEASE IN RENAL TRANSPLANT RECIPIENTS 
 
1. NAME 
 
2. AGE/SEX 
 
3. NATIVE KIDNEY DISEASE 
 
4. DONOR 
 
5. DATE OF RENAL TRANSPLANTATION 
 
6. HBV VACCINATION STATUS PRIOR TO TRANSPLANT 
 
7. BLOOD TRANSFUSION HISTORY 
 
8. PRE‐TRANSPLANTATION VIRAL SEROLOGY STATUS 
 
 
9.  TIME  DURATION  OF  OCCURENCE  OF  HEPATIC  DYSFUNCTION  FOLLOWING 
TRANSPLANT 
10. PRESENTING COMPLAINTS 
 
NAUSEA/VOMITING 
JAUNDICE 
PRURITUS 
ASCITES 
ABDOMINAL PAIN 
GI BLEED 
ENCEPHALOPATHY 
 
11. CLINICAL EXAMINATION 
 
ICTERUS 
SPIDER NAEVI 
PALMAR ERYTHEMA 
ASCITES 
PETECHIAE 
ASTEREXIS 
 
 
12. VITALS 
 
PULSE/TEMPERATURE/BLOOD PRESSURE/RR 
 
 
13. ABDOMINAL EXAMINATION 
 
ASCITES/PEDAL EDEMA 
HEPATOMEGALY/TENDERNESS LIVER/SPLENOMEGALY 
CAPUT MEDUSAE 
SCARS/SINUSES 
HERNIAL ORIFICES 
 
14. PR EXAMINATION 
 
15. EXAMINATION OF OTHER SYSTEMS 
 
CARDIOVASCULAR SYSTEM 
 
RESPIRATORY SYSTEM 
 
NERVOUS SYSTEM 
 
INVESTIGATIONS 
 
1. URINALYSIS 
 
2. BLOOD INVESTIGATIONS 
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PLATELET COUNT 
PERIPHERAL SMEAR 
BLOOD UREA, SERUM CREATININE, BLOOD SUGAR 
 
3. LIVER FUNCTION TESTS 
 
SERUM BILIRUBIN: DIRECT & INDIRECT FRACTIONS 
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4. URINE CULTURE&BLOOD CULTURE 
 
 
5. VIRAL SEROLOGY 
 
HEPATITIS B Ag, IgM Anti HBc, Hbe Ag, HBV DNA 
ANTI HCV ANTIBODY 
Pp65 Ag ASSAY FOR CMV 
 
6. CHEST X‐RAY 
 
7. EKG 
 
8. ULTRASOUND ABDOMEN 
 
9. CT ABDOMEN 
 
10. UPPER GI SCOPY 
 
11. RENAL BIOPSY (SELECT CASES) 
 
12. LIVER BIOPSY (SELECT CASES) 
 
 
 
 
 
 CONSENT FORM  
Title of Project: A STUDY OF LIVER DISEASE IN RENAL TRANSPLANT 
RECIPIENTS 
Name of Researcher:  
Please tick 
to confirm 
•I confirm that I have read and understand the information provided to me 
for the above study.  
•I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily.  
•I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.  

•I agree to take part in the above research study.  
 
__________________________
Name of Patient  
______________
Date 
__________________________
Signature 
__________________________
Name of Person taking consent 
(if different from researcher) 
______________
Date 
__________________________
Signature 
__________________________
Researcher 
______________
Date 
__________________________
Signature 
  
 
 
 
 
 
 
 
Sl.no Name  Age/sex Native kidney 
disease 
Donor  Date of 
transplant 
Immuno- 
suppression 
Ad. 
after Tx 
          Pre Tx workup 
Bl. 
Transf. 
HBV 
vaccine 
Viral 
serology 
1 Kulandaivelu  38/m Nk brother 03.01.2007 CsA/AZA/P 2 mo 2 units 3doses HCV 
2 Saravanan  28/m Nk  mother 14.07.2007 CsA/AZA/P 6 mo nil 2doses Neg 
3 Kuttan   40/m Nk sister 18.07.2008 CsA/AZA/P 4 mo nil 3doses Neg 
4 Rajeswari  22/f SLE/LN brother 05.04.1999 CsA/AZA/P 36mo nil 2doses Neg 
5 Kumar  29/m Nk mother 27.09.2007 CsA/AZA/P 9 mo nil 3doses Neg 
6 Thirumurugan  35/m IgAN sister 08.05.2008 CsA/AZA/P 12mo nil 3doses Neg 
7 Rajendran  26/m Nk mother 26.04.2007 CsA/AZA/P 10 mo  1unit 1doses Neg 
8 Velmurugan  32/m Stricture urethra father 26.03.2007 CsA/AZA/P 24mo nil 3doses Neg 
9 Prabhu   20/m IgAN father 18.07.2006 CsA/AZA/P 1 mo 2units 3doses Neg 
10 Balachander  31/m Nk sister 12.04.2007 CsA/AZA/P 6 mo 1unit 1doses Neg 
11 Davidrajan  49/m Nk sister 20.10.2003 CsA/AZA/P 48 mo 2units 3doses Neg 
12 Mustafakamal  31/m Nk brother 27.10.1998 CsA/AZA/P 108 mo nil 3doses Neg 
13 Rajesh kumar 25/m Nk mother 19.01.2007 CsA/AZA/P 2 mo 4units 3doses HCV 
14 Thangavel  38/m Nk sister 05.02.2006 CsA/AZA/P 15 mo nil 2doses Neg 
15 Vanniyaperumal  39/m Nk mother 16.06.2008 CsA/AZA/P 5 mo 5units 3doses HCV 
16 Asaithambi  27/m Nk sister 29.10.2007 CsA/AZA/P 6 mo nil 3doses Neg 
17 Sangeeta  17/f Nk mother 25.01.2005 CsA/AZA/P 6 mo nil 2doses Neg 
18 Kumari    33/f IgAN brother 19.02.2008 CsA/AZA/P 4 mo nil 3doses Neg 
19 Ganesan  35/m Nk brother 15.07.2008 CsA/AZA/P 7 mo nil 3doses Neg 
20 Elumalai  25/m vasculitis mother 10.06.2008 CsA/AZA/P 6 mo nil 1doses Neg 
 
 
 
Sl.no Name  Age/sex Native 
kidney 
disease 
Donor  Date of 
transplant 
Immuno-
suppression  
Admission 
after Tx 
          Pre Tx workup 
Blood 
Transf. 
HBV 
vaccine 
Viral 
serology 
21 Arul 30/m VUR mother 10.08.2007 CsA/AZA/P 5 mo nil 3doses Neg 
22 Mahesh  27/m Nk mother 28.04.2007 CsA/AZA/P 3 mo nil 3doses Neg 
23 Ravi  49/m Nk brother 23.01.2007 CsA/AZA/P 12 mo 5 units 1doses Neg
24 Murugesan  26/m IgAN mother 16.12.2008 CsA/AZA/P 1 mo nil 3doses Neg 
25 Murugesan  49/m Nk sister 14.07.2009 CsA/AZA/P 3 mo nil 3doses Neg 
26 Shahida begum 22/f VUR mother 18.08.2008 CsA/AZA/P 15 mo nil 2doses Neg 
27 Dakshinamoorthy  55/m Nk brother 15.06.1993 CsA/AZA/P 180 mo nil 3doses Neg 
28 Vinoth kumar 25/m VUR father 26.03..2009 CsA/AZA/P 11 mo nil 3doses Neg 
29 Jude Anthony 37/m Nk sister 11.05.2009 CsA/AZA/P 12mo nil 3doses Neg 
30 Siva kumar 26/m IgAN father 13.07.2009 CsA/MMF/P 5 mo 6 units 1doses Neg 
31 Divya  19/f Nk mother 11.04.2006 CsA/AZA/P 36 mo nil 3doses Neg 
32 Manikandan  23/m Nk mother 07.01.2008 CsA/AZA/P 3 mo nil 3doses Neg 
33 Siva   27/m SPGN mother 19.08.2004 CsA/AZA/P 6 mo nil 2doses HBsAg 
34 Gopalakrishnan  27/m MGN mother 07.03.2008 CsA/AZA/P 18 mo nil 3doses HCV 
35 Anbalagan  30/m Nk brother 27.02.2007 CsA/AZA/P 24 mo nil 1doses HBsAg 
 
 
 
 
 
 
 
 
 
 
Sno Name                                    Clinical presentation              LFT 
N/V Jaundice pruritus Encephalopathy Ascites GI 
bleed
Abd. 
pain 
T.Bil 
Mg/dl
D.Bil 
Mg/dl
OT/PT 
Iu/ml 
SAP 
Iu/ml
A/G 
g/dl 
1 Kulandaivelu  Yes Yes No No No No No 3.1 2.0 232/459 235 3.5/2.5
2 Saravanan  Yes Yes No No No No No 1.5 1.1 87/264 168 3.6/2.2
3 Kuttan   No No No No No No No 1.0 0.7 99/112 156 3.5/2.6
4 Rajeswari  No No No No No No No 1.0 0.7 88/136 172 3.5/2.6
5 Kumar  Yes Yes No No No No No 3.6 2.1 123/160 206 3.6/2.4
6 Thirumurugan  Yes Yes  Yes Yes No yes yes 40 26 80/84 211 4/2.5 
7 Rajendran  Yes Yes No No No No No 3.0 2.0 70/88 112 3.6/2.5
8 Velmurugan  Yes Yes Yes No Yes No yes 2.2 1.5 65/98 250 4/3 
9 Prabhu   Yes Yes No No No No No 1.3 0.9 48/38 202 3.8/2.2
10 Balachander  Yes Yes No No No No No 15.7 10.5 100/134 210 4/2.8 
11 Davidrajan  Yes Yes No No No No No 2.8 2.0 154/125 208 3.5/2.3
12 Mustafakamal  No No No No No No No 1.0 0.7 157/160 156 3.5/2.6
13 Rajesh kumar Yes Yes No No No No No 2.8 1.7 52/66 148 3.6/2.4
14 Thangavel  No No No No No No No 1.1 0.8 112/160 120 3.5/2.5
15 Vanniyaperumal  No No No No No No yes 1.8 1.0 66/88 157 3.5/2.5
16 Asaithambi  No No No No No No No 1.1 0.9 120/135 123 3.6/2.7
17 Sangeeta  Yes Yes No No No No No 4.8 3.3 310/132 236 3.4/2.5
18 Kumari    Yes Yes No No No No No 4.2 2.8 112/143 208 3.6/2.5
19 Ganesan  No No  No No No No No 1.1 0.8 88/155 120 3.5/2.5
20 Elumalai  Yes Yes Yes No No yes No 19.8 14.2 162/168 362 3.6/2,5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.no  Name                                     Clinical presentation              LFT 
N/V jaundice Pruritus encephalopathy ascites GI 
bleed 
Abd. 
pain 
T.Bil 
Mg/dl
D.Bil 
Mg/dl
OT/PT 
Iu/ml 
SAP 
Iu/ml
A/G 
g/dl 
21 Arul Yes Yes No No No No No 2.2 1.6 32/37 142 3.5/2.8
22 Mahesh  Yes Yes No No No No No 3.3 2.5 143/123 163 4.0/2.8
23 Ravi  No No No No No No No 1.0 0.8 88/122 208 4.2/2.9
24 Murugesan  No No No No No No No 1.5 0.9 112/138 212 3.8/2.4
25 MMurugesan  No No No No No No No 1.8 1.1 121/112 208 4.0/2.8
26 Shahida begum yes Yes Yes No yes No yes 14.4 8.7 121/145 389 3.2/2.9
27 Dakshinamoorthy  yes yes No No No No No 2.2 1.5 106/112 340 3.9/2.6
28 Vinoth kumar Yes Yes Yes No No No No 14.0 9.0 231/234 249 4.0/2.0
29 Jude anthony Yes Yes No No No No yes 1.6 1.1 78/84 150 4.1/2.9
30 Siva kumar Yes Yes No No No No No 2.8 1.9 120/123 140 3.6/2.5
31 Divya  No No No No No No No 1.0 0.8 184/248 290 3.4/3.3
32 Manikandan  No No No No No No No 8.1 6.2 77/140 220 3.6/2.6
33 Siva No  No  No No No No No 1.0 0.7 349/377 162 3.5/2.5
34 Gopalakrishnan  Yes Yes No No No No yes 3.4 2.2 145/189 180 3.6/2.6
35 Anbalagan  Yes Yes No No No No No 4.0 2.8 91/63 168 3.4/2.2
  
 
S.no Name  Proteinuria HB 
g/dl
TC 
/cmm 
 
Plt 
/cmm 
s.creat 
micmol
B.sug 
mmol
Viral 
serology 
USG 
abd 
UGIscopy Liv 
Bx 
Ren 
Bx 
Outcome 
Pt graft livdysfn
1 Kulandaivelu  + 13 5500 3.5 98 5.2 HCV  normal gastritis ND ND A N Imp 
2 Saravanan  FT  11 3500 1.8 88 5.4 Neg normal Not done ND ND A N Imp  
3 Kuttan   + 12 6600 2.2 110 6.2 Neg normal Not done ND ND A N Imp 
4 Rajeswari  2+ 10 7100 2.8 106 15.2 HCV normal gastritis ND ND A N Imp 
5 Kumar  NIL 14 6500 1.6 232 5.8 HBV normal Eso. 
Varices 
ND ND A GF DCLD 
6 Thirumurugan  3+ 8.0 6750 1.8 106 6.4 Neg normal Not done done ND D N DCLD 
7 Rajendran  NIL 13 11000 1.9 96 7.0 Neg normal Not done ND ND A N Imp 
8 Velmurugan  3+ 8.0 8000 2.4 75 5.3 Neg  normal Eso. 
Varices 
done done D GF worsen 
9 Prabhu   NIL 12 8840 2.3 88 4.9 HCV normal gastritis ND ND A N Imp 
10 Balachander  NIL 13 9600 2.7 90 5.0 Neg normal Not done ND ND A N Imp 
11 Davidrajan  FT 13 9200 2.3 109 17.3 HBV normal gastritis ND ND A N Imp 
12 Mustafakamal  3+ 7.0 8600 2.1 400 15.6 Neg normal Not done ND done D GF worsen 
13 Rajesh kumar FT 12 7300 2.5 101 5.2 HCV normal gastritis ND ND A N Imp
14 Thangavel  NIL 6.0 2500 0.5L 106 4.8 CMV normal esophagitis ND ND A N Imp 
15 Vanniyaperumal  3+ 8.8 8750 2.4 230 5.4 HCV normal Gastritis ND ND D GF worsen 
16 Asaithambi  NIL 7.5 2600 0.9L 98 5.6 CMV normal esophagitis ND ND A N Imp 
17 Sangeeta  NIL 12 6200 2.6 92 4.6 Neg normal Not done ND ND A N Imp 
18 Kumari    + 11 5800 2.4 93 18.2 Neg normal Not done ND ND A N Imp 
19 Ganesan  2+ 7.0 3700 0.8L 324 4.8 CMV normal esophagitis ND done A GF Imp 
20 Elumalai  + 8.0 3200 1.0L 105 16.7 CMV normal Esophagitis ND ND A N Imp 
 
 
 
 
S.no  
Name  
Proteinuria HB 
g/dl 
TC/ 
cmm 
Plt/cmm s.creat 
micmol
B.sug 
mmol
Viral 
serology 
USG 
abd 
UGIscopy Liv 
Bx 
Ren 
Bx 
Outcome 
Pt graft livdysfn
21 Arul FT 9.4 7600 2.2 245 5.3 Neg normal Not done ND ND D GF Imp 
22 Mahesh  + 7.6 3500 0.9L 88 5.8 CMV normal esophagitis ND ND A N Imp 
23 Ravi  + 8.6 8600 2.6 98 17.8 HCV normal Gastritis ND ND A N Imp 
24 Murugesan  2+ 8.5 4000 1.9 245 16.3 CMV normal esophagitis ND ND D GF Worsen 
25 Murugesan  NIL 8.0 3800 1.1L 110 4.7 CMV/HBV normal Esophagitis ND done A N Imp 
26 Shahida begum NIL 9.8 7700 2.0 103 5.1 Neg gallstone Not done ND ND A N Imp 
27 Dakshinamoorthy  2+ 10 6500 1.9 85 5.8 HCV normal Gastritis ND ND A N Imp 
28 Vinoth kumar 3+ 8.8 6700 1.8 135 5.3 Neg normal Not done ND done A N Imp 
29 Jude Anthony 2+ 9.7 12800 2.5 115 5.6 Neg normal Not done ND done A N Imp 
30 Siva kumar NIL 13.8 7200 2.6 100 4.9 HBV normal Gastritis ND ND A N Imp 
31 Divya  + 11.6 5700 2.0 397 5.3 HCV normal Gastritis ND done A GF Imp 
32 Manikandan  2+ 12.2 6500 2.3 94 5.7 Neg  normal Not done ND ND A N Imp 
33 Siva + 11 6700 2.4 86 4.9 Neg  normal Not done ND ND A N Imp 
34 Gopalakrishnan  3+ 9.2 7600 2.2 258 5.3 HCV normal Gastritis ND done A GF Imp 
35 Anbalagan  + 10.8 6500 2.3 224 5.5 HBV/HCV normal Gastritis ND ND A GF Imp 
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